Foliglurax

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Foliglurax
Foliglurax tautomer skeletal.svg
Clinical data
Synonyms DT-1687; PXT-002331; PXT-2331
Identifiers
PubChem CID
  • 129320518
ChemSpider
  • 59718537
Chemical and physical data
Formula C23H23N3O3S
Molar mass 421.515 g/mol g·mol−1
3D model (JSmol)
  • Interactive image

Foliglurax (developmental code names PXT-002331, DT-1687) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4) which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.[1][2] As of July 2017, it is in phase II clinical trials for this indication.[1]

The other tautomeric form of foliglurax.

References

  1. ^ a b http://adisinsight.springer.com/drugs/800044176
  2. ^ Ellis, J. Michael; Fell, Matthew J. (2017). "Current approaches to the treatment of Parkinson's Disease". Bioorganic & Medicinal Chemistry Letters. doi:10.1016/j.bmcl.2017.07.075. ISSN 0960-894X.

External links

  • Foliglurax - AdisInsight



Retrieved from "https://en.wikipedia.org/w/index.php?title=Foliglurax&oldid=833613846"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/Foliglurax
This page is based on the copyrighted Wikipedia article "Foliglurax"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA